Alloplex Biotherapeutics Stock

Alloplex Biotherapeutics is a biotechnology company that is developing novel, off-the-shelf allogeneic cell therapies for the treatment of cancer and other diseases. The company's proprietary platform, AlloCAR™, enables the engineering of T cells to express chimeric antigen receptors (CARs) that can recognize and attack tumor cells. Alloplex Biotherapeutics aims to transform the field of cell therapy by providing a scalable, cost-effective, and personalized approach to cancer treatment.